NYSE: GSK
Glaxosmithkline Plc Earnings & Revenue

GSK past earnings growth

How has GSK's earnings growth performed historically?
Company
27.41%
Industry
10.68%
Market
82.89%
GSK's earnings have grown faster (10.38% per year) than the US Drug Manufacturers - General industry average (8.89%)
Performance
GSK's earnings have grown slower (10.38% per year) than the US market average (77.34%)
Performance
GSK's earnings growth is accelerating - its growth over the last year (27.41%) is above its 5-year compound annual rate (10.38%)
Performance

GSK past revenue growth

How has GSK's revenue growth performed historically?
Company
9.52%
Industry
6.62%
Market
16.55%
GSK's revenue has grown faster (7.97% per year) than the US Drug Manufacturers - General industry average (4.07%)
Performance
GSK's revenue has grown slower (7.97% per year) than the US market average (15.67%)
Performance
GSK's revenue growth is accelerating - its growth over the last year (9.52%) is above its 5-year compound annual rate (7.97%)
Performance

GSK earnings and revenue history

Current Revenue
$33.8B
Current Earnings
$4.6B
Current Profit Margin
13.80%
GSK's has not demonstrated consistent long-term earnings growth over the past 10 years (-13.93%)
Performance

GSK Return on equity

Current Company
61.20%
Current Industry
36.30%
Current Market
14.90%
GSK's Return on Equity (61.20%) shows a company that is highly efficient at transforming shareholder equity into returns
Performance

GSK Return on assets

Current Company
6.70%
Current Industry
9.40%
Current Market
6.90%
GSK is generating lower Return on Assets (6.70%) than the US Drug Manufacturers - General industry average (8.27%)
Performance

GSK Return on capital employed

Current Company
11.70%
Current Industry
14.40%
GSK has gotten more efficient at generating Return on Capital (11.70%) compared to 3 years ago (6.30%)
Performance

Glaxosmithkline Earnings & Revenue FAQ

As of Q4 2020, Glaxosmithkline's earnings has grown 27.41% year over year. This is 16.73 percentage points higher than the US Drug Manufacturers - General industry earnings growth rate of 10.68%. Glaxosmithkline's earnings in the past year totalled $4.65 billion.
As of Q4 2020, Glaxosmithkline's revenue has grown 9.52% year over year. This is 2.90 percentage points higher than the US Drug Manufacturers - General industry revenue growth rate of 6.62%. Glaxosmithkline's revenue in the past year totalled $33.75 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Heap | Mobile and Web Analytics